The Summary
Researchers conducted a literature review to evaluate the off-label use of topical sirolimus (rapamycin) for various dermatological conditions. They excluded common vascular anomalies to focus on lesser-known applications like genetic skin disorders, benign tumors, and inflammatory eruptions. The review found that topical rapamycin is highly effective for conditions such as pachyonychia congenita and Kaposi sarcoma, demonstrating a favorable safety profile with minimal systemic absorption into the bloodstream. However, the authors noted that larger-scale studies are needed to standardize formulations and dosing regimens.
Why this is interesting
Rapamycin is a well-known immunosuppressant, but its topical form is currently only approved for a very specific skin condition. This review highlights its massive untapped potential as a versatile, safe cream for a broader range of stubborn issues, from genetic disorders to benign skin tumors. Because it acts locally without being heavily absorbed into the bloodstream, it limits body-wide side effects. For readers, this means dermatologists may soon have a powerful, safe new tool in their arsenal for treating frustrating skin conditions that do not respond to standard therapies.